EQ Equillium Bio Forward Price-to-Revenue Multiple
Equillium, Inc. attracts leading clinicians and retains scientists through stock option programs. The business relies on the development of anti-inflammatory immunotherapies and partnerships with industry leaders. Management strictly controls expenses and transparently discloses research phases. The forward P/S valuation metric reflects market expectations, with the value fixed at 28.50.
equilliumbio.com (EQ) - metric breakdowns and financial figures
- market price and analyst price targets:
- market capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
EQ - Final Profit|Projected Future Earnings Equillium, Inc.|EQ - Business Payback Period|Future Price to Earnings Equillium|EQ - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple EQ|EQ - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Equillium|EQ - Net earnings per share for the last four quarters|Quarterly EPS earnings growth equilliumbio.com|EQ - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Equillium, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:Equillium Bio (EQ)
Forward P/S reflects the market value of the business relative to projected annual revenue, allowing for a real-time assessment of the premium paid for future cash flows. By analyzing the expected P/S trend, an investor can compare the speculative value of Equillium, Inc. (EQ) with the prospects for the commercialization of immunomodulatory therapy by 2026, determining the asset's resilience in the face of clinical risks.
Competitors of Equillium, Inc.
Price-to-Projected Revenue Ratio argenx ARGX|Projected Price to Revenue BioNTech Inc.|ABVX: Forward Price-to-Revenue Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|IMVT - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Kiniksa|Price-to-Projected Revenue Ratio GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Corp)|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|VERA: Forward Price-to-Revenue Multiple|DNTH - Forward P/S Multiple|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple AbCellera Corp|Forward Price-to-Revenue Multiple TRML|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|Market Cap to Expected Sales Ratio Nektar Therapeutics Inc|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|ZBIO: Market Cap to Projected Revenue|Immunome, Inc. - Forward P/S Multiple|gossamerbio.com (GOSS) - Forward Price-to-Revenue Multiple|KALV (KalVista Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|SEPN - Market Cap to Expected Sales Ratio|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Savara Pharma SVRA|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|anaptysbio.com (ANAB) - Projected Price to Revenue|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN (enGene Holdings Inc) - Future Price to Revenue|RAPT Therapeutics, Inc. - Forward P/S Multiple|Forward Price to Sales JBIO (Aerovate Therapeutics Inc)|ACRS: Forward P/S Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|CABA: Forward Price to Sales|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Forward Price-to-Revenue Multiple Theratechnologies, Inc THTX|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|Forward P/S Multiple eledon.com ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio Inc.)|ZURA: Forward P/S Multiple|ATYR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adagene Inc|Forward Price-to-Revenue Multiple Ikena Oncology, Inc. (IMA)|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|Forward Price-to-Revenue Multiple connectbiopharm.com CNTB|Immunic - Forward Price-to-Revenue Multiple|Forward P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR (x4pharma.com) - Market Cap to Projected Revenue|ACET: Forward P/S Multiple|Market Cap to Future Revenue Ratio Celularity (CELU)|INMB (INmune Bio Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Barinthus Biotherapeutics Corp BRNS|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|sabbiotherapeutics.com (SABS) - Projected Price to Revenue|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|IBIO (ibioinc.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Price-to-Projected Revenue Ratio XTLB|Forward P/S Multiple BOLT|Market Cap to Expected Sales Ratio hcwbiologics.com|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple AIM ImmunoTech, Inc. AIM|ADTX - Price-to-Projected Revenue Ratio|GRI Bio Inc (GRI) - Forward Price-to-Revenue Multiple|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics - Forward Price to Sales|REVB (Revelation Biosciences) - Forward P/S Multiple|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|calcimedica.com - Market Cap to Projected Revenue|Forward P/S Multiple AFMD (Affimed N.V.)|ALLK - Forward Price-to-Revenue Multiple|HOOK: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|ITOS: Forward P/S Multiple|Market Cap to Future Revenue Ratio Ocean Biomedical Inc (OCEA)|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|THRD - Projected Price to Revenue
